Farletuzumab, which is a humanized monoclonal antibody that binds to FRα, is currently being investigated in phase II clinical trial (clinical Trials.gov identifier: NCT01218516) in NSCLC adenocarcinoma patients. This evidence concerns the gene FOLR1 and adenocarcinoma.